GlassScriptPhysician profile
Brian J Karp
NPI 1073657409
$5,587.48
in general payments reported to CMS, 2019-2025
25 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.05 · 2021: $70.25 · 2022: $113 · 2023: $1,241 · 2024: $1,991 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,383.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.29 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $735.10 | 2023-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $460.44 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $456.71 | 2023-2025 | Entyvio |
| Madrigal Pharmaceuticals | $428.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $358.07 | 2022-2025 | Dupixent |
| Genzyme Corporation | $334.23 | 2023-2025 | |
| Daiichi Sankyo INC. | $311.79 | 2020-2025 | Injectafer |
| Celgene Corporation | $287.34 | 2022-2024 | Zeposia |
| Pfizer INC. | $183.71 | 2023-2025 | |
| Ardelyx, INC. | $129.02 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $126.82 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $76.10 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $66.64 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $42.76 | 2023-2024 | Terlivaz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $37.32 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $36.41 | 2023-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $33.85 | 2023-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $28.71 | 2024 | Voquezna |
| Organon LLC | $28.58 | 2023 | Hadlima, Renflexis |
| Ucb, INC. | $23.30 | 2023 | Cimzia |
| Fresenius Kabi USA, LLC | $21.90 | 2023 | Idacio |
| Evoke Pharma, INC. | $17.93 | 2023 | Gimoti |
| Orphalan INC | $14.12 | 2024 | Cuvrior |
| Meridian Bioscience INC. | $13.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Karp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.